wr 99210 has been researched along with dapsone in 3 studies
| Studies (wr 99210) | Trials (wr 99210) | Recent Studies (post-2010) (wr 99210) | Studies (dapsone) | Trials (dapsone) | Recent Studies (post-2010) (dapsone) |
|---|---|---|---|---|---|
| 59 | 0 | 12 | 5,116 | 379 | 862 |
| Protein | Taxonomy | wr 99210 (IC50) | dapsone (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 0.42 | |
| Dihydrofolate reductase | Pneumocystis carinii | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genther, CS; Smith, CS | 1 |
| Cynamon, MH; Majumder, SK; Meyer, SC | 1 |
| Cynamon, MH; DeStefano, MS; Shah, LM | 1 |
3 other study(ies) available for wr 99210 and dapsone
| Article | Year |
|---|---|
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
Topics: Animals; Antimalarials; Bacteria; Drug Resistance, Microbial; Escherichia coli; Folic Acid; Folic Acid Antagonists; Malaria; Mice; Plasmodium berghei; Triazines | 1977 |
In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex.
Topics: Antimalarials; Cyclization; Dapsone; Folic Acid Antagonists; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Proguanil; Triazines | 1995 |
Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex.
Topics: Anti-Bacterial Agents; Dapsone; Drug Synergism; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Triazines | 1996 |